U19 Amyloid and assessments

1. Coordinate all human PET and MR imaging at U Penn, UCSF, Yale and WU.
   1. Standardize inclusion/exclusion criteria for patient groups - idiopathic PD, MSA, PSP, FTD and healthy controls.
   2. Harmonize PET scanning protocols and devices.
   3. Generate and coordinate all regulatory protocols including local Radiation Safety or Radioactive Drug Research Committee (or its equivalent) and implement a single IRB (at U Penn)
   4. Interact with multiple ongoing longitudinal cohorts of PD, MSA, PSP and FTD.
2. Implement a centralized data storage and distribution web-based site at WU for imaging and clinical data using well-established tools for web based clinical data collection (MARS) and XNAT for imaging data
3. Coordinate local approvals for administration of different A-beta amyloid radiotracers for these PET studies in humans.
4. Perform autoradiography with relevant radiotracers on fresh frozen postmortem tissues from those participants that die during the course of this study This is a pilot study. We will use descriptive statistics and paired statistical analyses to compare binding of the tracers in the whole brain and in regions of interest (ROIs) between each patient group and healthy controls. Ultimately, we will compare whole brain and regional uptake of the A-beta amyloid tracer with the to-be-developed alpha-synuclein or 4R tau radiotracers with those studies done under a separate protocol and approval Collection of brain autopsy specimens

You may be eligible for this study if you meet the following criteria:

• Conditions: Medical Research
• Age: 99 years or below
• Gender: All